Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel

Nature Chemical Biology

Volumn 7, Issue 9, 2011, Pages 595-601

  Liu, Fa ^a   Park, Jung Eun ^b   Qian, Wen Jian ^a   Lim, Dan ^c   Gräber, Martin ^d   Berg, Thorsten ^d   Yaffe, Michael B ^c   Lee, Kyung S ^b   Burke Jr , Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; HISTIDINE; IMIDAZOLE DERIVATIVE; LIGAND; MACROGOL; NITROGEN; POLO LIKE KINASE 1; POLO LIKE KINASE 1 POLO BOX DOMAIN BINDING PEPTIDE; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALKYLATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CENTROMERE; CENTROSOME; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME STABILITY; FLUORESCENCE POLARIZATION; HYDROLYSIS; IC 50; MITOSIS; PEGYLATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 84860388896     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.614     Document Type: Article

References (49)

1. Barr, F.A., Sillje, H.H.W. & Nigg, E.A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5, 429-440 (2004). (Pubitemid 38745493)
2. Dai, W. Polo-like kinases, an introduction. Oncogene 24, 214-216 (2005). (Pubitemid 40188601)
3. Lowery, D.M., Lim, D. & Yafe, M.B. Structure and function of polo-like kinases. Oncogene 24, 248-259 (2005). (Pubitemid 40188605)
4. van de Weerdt, B.C.M. & Medema, R.H. Polo-like kinases: a team in control of the division. Cell Cycle 5, 853-864 (2006). (Pubitemid 44145580)
5. Archambault, V. & Glover, D.M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. 10, 265-275 (2009).
6. Strebhardt, K. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330 (2006).
7. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005). (Pubitemid 40188607)
8. Takai, N., Hamanaka, R., Yoshimatsu, J. & Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 24, 287-291 (2005). (Pubitemid 40188609)
9. Goh, K.C. et al. PLK1 as a potential drug target in cancer therapy. Drug Dev. Res. 62, 349-361 (2004).
10. McInnes, C., Mezna, M. & Fischer, P.M. Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197 (2005). (Pubitemid 40514514)
11. Gumireddy, K. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275-286 (2005). (Pubitemid 40568686)
12. Lansing, T.J. et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol. Cancer Ter. 6, 450-459 (2007). (Pubitemid 46332447)
13. Lénárt, P. et al. Te small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol. 17, 304-315 (2007).
14. Lu, L.-Y. & Yu, X. Te balance of Polo-like kinase 1 in tumorigenesis. Cell Div. 4, 4 (2009).
15. Reindl, W., Yuan, J., Kraemer, A., Strebhardt, K. & Berg, T.A. Pan-specifc inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. ChemBioChem 10, 1145-1148 (2009).
16. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010).
17. Burns, T.F., Fei, P., Scata, K.A., Dicker, D.T. & El-Deiry, W.S. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol. Cell. Biol. 23, 5556-5571 (2003). (Pubitemid 36951322)
18. Xie, S., Xie, B., Lee, M.Y. & Dai, W. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24, 277-286 (2005). (Pubitemid 40188608)
19. Elia, A.E.H., Cantley, L.C. & Yafe, M.B. Proteomic screen fnds pSer/pTr-binding domain localizing Plk1 to mitotic substrates. Science 299, 1228-1231 (2003). (Pubitemid 36237463)
20. Elia, A.E.H. et al. Te molecular basis for phosphodependent substrate targeting and regulation of Plks by the polo-box domain. Cell 115, 83-95 (2003). (Pubitemid 37255320)
21. Cheng, K.-Y., Lowe, E.D., Sinclair, J., Nigg, E.A. & Johnson, L.N. Te crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 22, 5757-5768 (2003). (Pubitemid 37408815)
22. Reindl, W., Yuan, J., Kraemer, A., Strebhardt, K. & Berg, T. Inhibition of Polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions. Chem. Biol. 15, 459-466 (2008). (Pubitemid 351645109)
23. Yun, S.-M. et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat. Struct. Mol. Biol. 16, 876-882 (2009).
24. Watanabe, N. et al. Defciency in chromosome congression by the inhibition of Plk1 Polo box domain-dependent recognition. J. Biol. Chem. 284, 2344-2353 (2009).
25. Jang, Y.-J., Lin, C.-Y., Ma, S. & Erikson, R.L. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl. Acad. Sci. USA 99, 1984-1989 (2002). (Pubitemid 34169001)
26. Lee, K.S., Grenfell, T.Z., Yarm, F.R. & Erikson, R.L. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc. Natl. Acad. Sci. USA 95, 9301-9306 (1998). (Pubitemid 28506226)
27. Seong, Y.-S. et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J. Biol. Chem. 277, 32282-32293 (2002). (Pubitemid 34969045)
28. Wipf, P. et al. A case study from the chemistry core of the Pittsburgh molecular library screening center: the polo-like kinase polo-box domain (Plk1-PBD). Curr. Top. Med. Chem. 9, 1194-1205 (2009).
29. Li, L. et al. Te natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmacol. Sin. 30, 1443-1453 (2009).
30. García-Alvarez, B., de, C.G., Ibanez, S., Bragado-Nilsson, E. & Montoya, G. Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc. Natl. Acad. Sci. USA 104, 3107-3112 (2007). (Pubitemid 46364121)
31. Huggins, D.J. et al. Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation. PLOS Comput. Biol. 6, e1000880 (2010).
32. Liu, F., Park, J.-E., Lee, K.S. & Burke, T.R. Jr. Preparation of orthogonally protected (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of polo-box domain-binding peptides. Tetrahedron 65, 9673-9679 (2009).
33. Swamy, K.C.K., Kumar, N.N.B., Balaraman, E. & Kumar, K.V.P.P. Mitsunobu and related reactions: advances and applications. Chem. Rev. 109, 2551-2651 (2009).
34. McGovern, S.L. Promiscuous ligands. Compr. Med. Chem. II 2, 737-752 (2006).
35. Coan, K.E.D., Maltby, D.A., Burlingame, A.L. & Shoichet, B.K. Promiscuous aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem. 52, 2067-2075 (2009).
36. Bhadra, D., Bhadra, S., Jain, P. & Jain, N.K. Pegnology: a review of PEG-ylated systems. Pharmazie 57, 5-29 (2002). (Pubitemid 34101777)
37. Roberts, M.J., Bentley, M.D. & Harris, J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476 (2002). (Pubitemid 34615543)
38. Pisal, D.S., Kosloski, M.P. & Balu-Iyer, S.V. Delivery of therapeutic proteins. J. Pharm. Sci. 99, 2557-2575 (2010).
39. Tsuchida, E. et al. Artifcial oxygen carriers, hemoglobin vesicles and albumin-hemes, based on bioconjugate chemistry. Bioconjug. Chem. 20, 1419-1440 (2009).
40. Miller, M.A. et al. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjug. Chem. 17, 267-274 (2006).
41. Khedkar, A. et al. A dose range fnding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12, 659-664 (2010).
42. Bellouard, F., Chuburu, F., Yaouanc, J.-J., Handel, H. & Le Mest, Y. A convenient synthetic route to polyether-tagged cyclam ligands and their nickel derivatives. Eur. J. Org. Chem. 1999, 3257-3261 (1999).
43. Kanda, Y., Ashizawa, T., Kawashima, K., Ikeda, S.-i. & Tamaoki, T. Synthesis and antitumor activity of novel C-8 ester derivatives of leinamycin. Bioorg. Med. Chem. Lett. 13, 455-458 (2003). (Pubitemid 36259712)
44. Ahonen, L.J. et al. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr. Biol. 15, 1078-1089 (2005). (Pubitemid 40841350)
45. Sledz, P. et al. From crystal packing to molecular recognition: Prediction and discovery of a binding site on the surface of polo-like kinase 1. Agnew Chem. Int. Ed. Engl. 50, 4003-4006 (2011).
46. Liu, X. & Erikson, R.L. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2, 424-425 (2003).
47. Luo, J. et al. A Genome-wide RNAi screen identifes multiple synthetic lethal interactions with the ras oncogene. Cell 137, 835-848 (2009).
48. Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106, 3964-3969 (2009).
49. Kang, Y.H. et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome regulation. Mol. Cell. 24, 409-422 (2006). (Pubitemid 44754942)